Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Tuesday, January 20, 2009

Clinical Data inks partnership in China

By Mass High Tech staff

Biotechnology company Clinical Data Inc. has announced that its Cogenics division has partnered with SinoGenoMax Co. in an effort to expand in China, Clinical Data officials reported.

The companies did not provide financial terms of the deal.

Clinical Data (Nasdaq: CLDA) provides gene sequencing and expression services as well as biomanufacturing support, nucleic acid extraction and ‘biobanking,’ and services for life sciences companies.

Newton-based Clinical Data, which employs 459 workers, reported a 2008 net loss of $35.3 million on revenue of $34 million during its fiscal year ending March 31. It has facilities in North Carolina, Texas, the U.K., France and Germany.

SinoGenoMax, based in Beijing, provides similar services and has an established distribution system serving China-based customers.



 

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women to Watch: What makes them special

By James M. Connolly Intelligence, dedicated, leader, innovative, hard-working — they’re all words associated with the 11 women recognized with the Mass High Tech Women to Watch awards this morning. But back at the office we were talking how commonly another word has to be applied to the 2010 honorees and their 60 predecessors. It’s their humility. It’s so striking. We at Mass High T...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio